Genitourinary Cancer
News
Nivolumab has survival benefit across diverse RCC patient subgroups
Key clinical point: Nivolumab was superior to everolimus regardless of disease characteristics and prior therapies. Major finding: All subgroups...
Conference Coverage
Liquid biopsy may help guide treatment decisions in prostate cancer
Key clinical point: In patients with castration-resistant metastatic prostate cancer, CTC heterogeneity affects the response to hormonal therapy...
News
METEOR: Cabozantinib bests everolimus across renal cancer subgroups
Key clinical point: Cabozantinib appears more efficacious than does everolimus for a wide range of patients. Major finding: Progression-free...
Conference Coverage
Risk of lethal prostate cancer is lower for regular aspirin users
Key clinical point: Regular aspirin use may reduce the risk of developing advanced prostate cancer and dying from the disease. Major finding: Men...
News
SLCO2B1 gene variants may influence ADT outcome
Key clinical point: Single-nucleotide polymorphisms rs12422149 and rs1077858 in the SLCO2B1 gene were associated with time to progression and...
News
ADT linked to increased risk of Alzheimer’s disease
Key clinical point: Patients who underwent ADT for prostate cancer had significantly increased risk of future Alzheimer’s disease diagnosis. Major...
News
FDA approves nivolumab for metastatic renal cell carcinoma
Approval was based on improvement in overall survival in CheckMate 025, an open-label, randomized study of 821 patients with advanced renal cell...
News
New bladder cancer drug fails first hurdle
News
Pan-AKT inhibitor shrinks tumors in patients with AKT1 mutation
A novel pan-AKT inhibitor shrinks tumors in patients harboring a mutation in AKT1.
News
More evidence for extended ADT after radiation therapy for prostate cancer patients
Key clinical point: ADT continued for 2 years is associated with significantly better outcomes than stopping at 4 months in men with localized...